Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Oxirapentyn A, Derived from Marine Amphichorda felina, Effectively Inhibits Quorum Sensing and Biofilm Formation Against Chromobacterium violaceum.

Created on 27 Mar 2025

Authors

Ying-Jie Wang, Fang Wang, Ming-Hua Jiang, Kai-Zhong Xu, Owias Iqbal Dar, Shi Tang, Lan Liu, Sen-Hua Chen, Ai-Qun Jia

Published in

Current microbiology. Volume 82. Issue 5. Pages 215. Mar 27, 2025. Epub Mar 27, 2025.

Abstract

The emergence of multidrug-resistant Chromobacterium violaceum, an opportunistic pathogen, poses a significant threat to human, animal, and environmental health, underscoring the urgent need for innovative strategies. Marine-derived natural compounds have gained attention as a promising source of quorum sensing inhibitors (QSIs) that can attenuate C. violaceum virulence without inducing resistance. This study reports, for the first time, the anti-quorum sensing (anti-QS) and anti-biofilm activities of oxirapentyn A, one marine natural compound, against C. violaceum. Results demonstrate oxirapentyn A (200 μg/mL) significantly inhibits biofilm formation, violacein production, and hemolysin synthesis by 48.8, 21.7, and 22.3%, respectively. Scanning electron microscopy (SEM) further corroborated the disruption of biofilm architecture. LC-MS analysis revealed a concentration-dependent reduction in the production of N-decanoyl-homoserine lactone (C10-HSL), a key QS signaling molecule. Furthermore, RT-qPCR analysis indicated oxirapentyn A downregulated critical QS-related genes (cviI, cviR, vioA, chiA, and pykF) by 20.7, 36.6, 31.1, 66.6, and 30.7%, respectively. Notably, in vivo experiments demonstrated that oxirapentyn A significantly improved the survival of Galleria mellonella larvae infected with C. violaceum. Collectively, these findings highlight oxirapentyn A as a novel QSI with dual anti-QS and biofilm-disrupting activities, offering a promising strategy to combat drug-resistant bacterial infections.

PMID:
40146334
Bibliographic data and abstract were imported from PubMed on 27 Mar 2025.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 17
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement